DRTSW Overview

Pilot Study Initiation: Alpha Tau Medical has commenced a multi-center pilot study, IMPACT, to evaluate the safety and efficacy of Alpha DaRT combined with chemotherapy for patients with newly diagnosed unresectable pancreatic adenocarcinoma, a condition affecting up to 87% of patients at diagnosis.

Innovative Treatment Approach: The study aims to provide a localized treatment option using Alpha DaRT's targeted alpha radiation, potentially improving outcomes for patients with limited treatment options, while continuing their standard chemotherapy regimen.

Company Announcement: Alpha Tau Medical Ltd. announced that CFO Raphi Levy will present at five investor conferences in September 2025, focusing on their innovative cancer therapy, Alpha DaRT.

Alpha DaRT Technology: The Alpha DaRT platform utilizes localized alpha particle radiotherapy to target solid tumors while minimizing damage to surrounding healthy tissue, with promising immuno-stimulatory effects.

Upcoming Conferences: Key events include the Citi 2025 Biopharma Summit, H.C. Wainwright Global Investment Conference, and others, where Mr. Levy will be available for one-on-one meetings with investors.

Forward-Looking Statements: The press release contains forward-looking statements regarding clinical trials and regulatory approvals, highlighting uncertainties and potential risks associated with the company's future performance.

Upcoming Investor Conferences: Alpha Tau Medical Ltd. will have CFO Raphi Levy presenting at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, and participating in 1x1 meetings at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025.

About Alpha Tau Medical: Founded in 2016, Alpha Tau focuses on developing the Alpha DaRT therapy for treating solid tumors, utilizing a method that delivers alpha radiation directly to tumors while minimizing damage to surrounding healthy tissue.

MDSAP Certification Achievement: Alpha Tau Medical Ltd. has received MDSAP certification for its manufacturing facility in Jerusalem, enhancing its commitment to quality and regulatory compliance while facilitating the global expansion of its alpha-radiation cancer therapy, Alpha DaRT.

Alpha DaRT Technology Overview: The Alpha DaRT therapy is designed for targeted treatment of solid tumors through intratumoral delivery of radium-224, aiming to effectively destroy tumor cells while minimizing damage to surrounding healthy tissue.

Alpha DaRT Clinical Trials: Positive interim results from multiple clinical trials of Alpha DaRT for pancreatic cancer and head and neck squamous cell carcinoma show high disease control rates, improved overall survival compared to historical benchmarks, and strong safety profiles.

Regulatory Approvals: The FDA has granted an Investigational Device Exemption for a U.S. pilot study combining Alpha DaRT with chemotherapy for metastatic pancreatic cancer, while France's Ministry of Health approved a multicenter trial using Alpha DaRT alongside capecitabine for locally advanced pancreatic cancer.

Alpha Tau Medical Announcement: Alpha Tau Medical Ltd. has had an abstract accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, focusing on their alpha-radiation therapy, Alpha DaRT, for pancreatic cancer.

R&D Update Day: The company will host an R&D Update Day to discuss new data from their clinical trials, including findings related to the safety and efficacy of Alpha DaRT in treating various cancers.